195 related articles for article (PubMed ID: 24028766)
1. Modulating the immune response to Bacillus Calmette-Guérin (BCG): a novel way to increase the immunotherapeutic effect of BCG for treatment of bladder cancer?
Sapre N; Corcoran NM
BJU Int; 2013 Oct; 112(6):852-3. PubMed ID: 24028766
[No Abstract] [Full Text] [Related]
2. Should intravesical Bacillus Calmette-Guérin be employed in transplant recipients with bladder carcinoma?
Sun HY; Singh N
Transpl Infect Dis; 2010 Aug; 12(4):358-62. PubMed ID: 20412534
[TBL] [Abstract][Full Text] [Related]
3. BCG prophylaxis in bladder cancer produces activation of recruited neutrophils.
Vita F; Siracusano S; Abbate R; Ciciliato S; Borelli V; Soranzo MR; Zabucchi G
Can J Urol; 2011 Feb; 18(1):5517-23. PubMed ID: 21333042
[TBL] [Abstract][Full Text] [Related]
4. Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder.
Ardelt PU; Kneitz B; Adam P; Reiss C; Kocot A; Fensterle J; Chen L; Pasqualini R; Arap W; Gerharz EW; Riedmiller H
Cancer; 2010 Feb; 116(3):600-9. PubMed ID: 19957324
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
[TBL] [Abstract][Full Text] [Related]
6. Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guérin substrains.
Secanella-Fandos S; Luquin M; Julián E
J Urol; 2013 Feb; 189(2):711-8. PubMed ID: 22982433
[TBL] [Abstract][Full Text] [Related]
7. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder.
Rosevear HM; Lightfoot AJ; O'Donnell MA; Griffith TS
Cancer Metastasis Rev; 2009 Dec; 28(3-4):345-53. PubMed ID: 19967427
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cellular immunity following bacillus Calmette-Guérin therapy in patients with superficial bladder cancer.
Sarica K; Baltaci S; Bedük Y; Süzer O; Kiliç S; Müftüğlu YZ; Göğüş O
Urol Int; 1995; 54(3):137-41. PubMed ID: 7604454
[TBL] [Abstract][Full Text] [Related]
9. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
10. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
11. BCG pyelonephritis following intravesical therapy for transitional cell carcinoma.
Garcia JE; Thiel DD; Broderick GA
Can J Urol; 2007 Apr; 14(2):3523-5. PubMed ID: 17466161
[TBL] [Abstract][Full Text] [Related]
12. [The bacillus Calmette-Guérin as immunomodulator in bladder cancer].
Vázquez-Lavista LG; Flores-Balcázar CH; Llorente L
Rev Invest Clin; 2007; 59(2):146-52. PubMed ID: 17633803
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
14. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
15. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
[TBL] [Abstract][Full Text] [Related]
16. Mathematical model of pulsed immunotherapy for superficial bladder cancer.
Bunimovich-Mendrazitsky S; Byrne H; Stone L
Bull Math Biol; 2008 Oct; 70(7):2055-76. PubMed ID: 18716846
[TBL] [Abstract][Full Text] [Related]
17. Granulomatous epididymo-orchitis, a rare complication of intravesical bacillus Calmette-Guérin therapy for urothelial cancer.
Harving SS; Asmussen L; Roosen JU; Hermann G
Scand J Urol Nephrol; 2009; 43(4):331-3. PubMed ID: 19396724
[TBL] [Abstract][Full Text] [Related]
18. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
Chen F; Zhang G; Cao Y; Hessner MJ; See WA
J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
[TBL] [Abstract][Full Text] [Related]
19. Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
Chen F; Zhang G; Cao Y; Payne R; See WA
J Urol; 2007 Nov; 178(5):2166-70. PubMed ID: 17870116
[TBL] [Abstract][Full Text] [Related]
20. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.
Morales A; Eidinger D; Bruce AW
J Urol; 1976 Aug; 116(2):180-3. PubMed ID: 820877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
